Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
VR

NASDAQ · VRCA

Verrica Pharmaceuticals Inc.

Healthcare · Biotechnology

$3.35

Down-$0.07 (-2.05%)

Updated Nov 1, 2026, 2:33 AM

SID Score

3.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
79.81M
P/E ratio
-3.07
Dividend yield
0.00%
52-week range
$3.25 – $8.50
Volume
33.79K
Avg. volume
399.36K

Price performance · VRCA

VRCA price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

VRCA closed at $3.35 after 20 trading sessions, down 22.27% for the selected period.

Last close
$3.35
Period change
-22.27%
Period low
$3.35
Period high
$4.31
Daily close
View OHLC price history
VRCA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$3.42$3.49$3.25$3.3533.79K
Oct 29, 2026$3.48$3.62$3.39$3.4229.72K
Oct 28, 2026$3.45$3.565$3.39$3.4822.37K
Oct 27, 2026$3.36$3.52$3.335$3.4727.99K
Oct 26, 2026$3.55$3.68$3.39$3.4221.94K
Oct 23, 2026$3.76$3.76$3.40$3.5321.01K
Oct 22, 2026$3.50$4.17$3.50$3.83109.91K
Oct 21, 2026$3.46$3.64$3.4414$3.6360.44K
Oct 20, 2026$3.44$3.56$3.30$3.4777.18K
Oct 19, 2026$3.61$3.645$3.42$3.4479.83K
Oct 16, 2026$3.85$3.95$3.48$3.595116.47K
Oct 15, 2026$3.92$3.95$3.746$3.7864.3K
Oct 14, 2026$3.54$3.92$3.50$3.8354.86K
Oct 13, 2026$3.99$4.38$3.51$3.5885.86K
Oct 12, 2026$4.20$4.20$4.00$4.0148.71K
Oct 9, 2026$4.37$4.37$4.06$4.1146.55K
Oct 8, 2026$4.14$4.29$4.05$4.1837.19K
Oct 7, 2026$4.15$4.3299$4.06$4.1447.65K
Oct 6, 2026$4.36$4.41$4.17$4.2141.31K
Oct 5, 2026$4.34$4.5387$4.25$4.3135.04K

Latest VRCA news

The latest Smart Investors Daily articles mentioning VRCA.

Stock researchCompany · Overview

VRCA research

Overview

Company profile and research snapshot.

Company profile

Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$12.00
Implied upside
—
Analysts
12
VRCA recent ratings
DateFirmRatingTarget
Dec 18, 2025Brookline CapitalBuy—
May 14, 2025NeedhamHold—
Apr 9, 2025NeedhamHold—
Apr 8, 2025HC Wainwright & Co.Neutral—
Mar 12, 2025NeedhamHold—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 22, 2026

Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit Facility

– Company’s achievement of pre-defined revenue, growth and operational milestones increases facility commitment by $15.0 million – – Capital now available to support continued growth of the YCANTH® business and advancement of the Company’s global Phase 3 common warts program through topline data readouts, the first of which is expected in Q1’27 – WEST CHESTER, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (Nasdaq: VRCA), a therapeutics company d

Benzinga · Oct 14, 2026

Verrica Pharmaceuticals Q2 2026 Earnings Call Transcript

Verrica Pharmaceuticals (NASDAQ:VRCA) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial

Yahoo · Sep 30, 2026

Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences

– Analysis shows YCANTH achieved complete clearance of molluscum contagiosum approximately 4 times faster than vehicle, regardless of disease duration – WEST CHESTER, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it will present posters on a new analysis of Phase 3 trials of

Yahoo · Sep 10, 2026

Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences

– Post-hoc analysis shows YCANTH® drove high rates of complete clearance in molluscum contagiosum patients regardless of disease duration – WEST CHESTER, Pa., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it will present posters on YCANTH® (VP-102), a therapy approved by the FDA

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By